[ad_1]
Broadcast Date: July 19, 2022
Time: 11:00 am PT, 1:00 pm ET, 20:00 CET
Figuring out novel tumor antigens is crucial for creating a continuous arsenal of potential therapeutic merchandise to enhance affected person care and outcomes. That is the underlying foundation for creating efficient most cancers vaccines that may attain a broad affected person inhabitants. Transcriptomic strategies like RNAseq proceed to point out their worth in figuring out new tumor antigens. Nonetheless, this expertise is proscribed because of the inherent heterogeneity discovered in lots of tumors. Investigators have begun to make use of methods comparable to single-cell RNA seq (scRNAseq) to restrict the drawbacks of tissue heterogeneity. Whereas there are a number of strategies and workflows that produce dependable scRNAseq information, analysis information has proven that the dissociation and purification of tumor cell populations considerably enhance scRNAseq outcomes.
On this GEN webinar, we’ll focus on scRNAseq research performed with Discovery Life Sciences and Astellas Pharma utilizing approaches that apply tumor tissue scRNAseq information for translational analysis, together with the identification of most cancers varieties for immuno-oncology initiatives. Discovery Life Sciences has optimized the acquisition, transport, processing, and cryopreservation of major human tissues for downstream evaluation. These cryopreserved dissociated tumor cells present the chance to know tumor heterogeneity on the single-cell degree utilizing 10X Genomics single-cell pipelines. Moreover, we’ll hear how scRNAseq information was utilized to find tumor antigens which are particularly expressed in malignant cells throughout the tumor.
A reside Q&A session will comply with the presentation, providing you an opportunity to pose inquiries to our knowledgeable panelists.
[ad_2]
